查詢結果分析
來源資料
相關文獻
- 治療性血管新生--利用肌肉注射含有人類血管內皮生長因子165的質體去氧核醣核酸,用以治療危急性下肢缺血的病人
- Delivery of a Vector with Vascular Endothelial Growth Factor Gene to the Pluripotent Stem Cell for Gene Therapy
- 黑鯛第一型類胰島素生長因子之融合蛋白質溶解性的研究
- Phytoplasmas are not Associated with Quick Decline of Macadamia Trees in Hawaii
- 動物的基因轉殖
- Recent Advances in Gene Therapy of GI and Liver Diseases
- 立枯絲核菌對賓克隆殺菌劑抗性及敏感性菌株之質體狀DNA的差異分析
- 利用多型性增幅聚合酵素連鎖反應建立弧菌與其質體之分子分型
- 論ISO9000族標準中的品質體系
- 微脂粒:製藥產業的未來!
頁籤選單縮合
題 名 | 治療性血管新生--利用肌肉注射含有人類血管內皮生長因子165的質體去氧核醣核酸,用以治療危急性下肢缺血的病人=Therapeutic Angiogenesis: Intramuscular Vascular Endothelial Growth Factor Gene Therapy for Patients with Chronic Critical Leg Ischemia |
---|---|
作 者 | 徐國基; | 書刊名 | 輔仁醫學期刊 |
卷 期 | 5:1 2007.03[民96.03] |
頁 次 | 頁9-16 |
分類號 | 415.384 |
關鍵詞 | 慢性危急性下肢缺血; 血管內皮生長因子; 質體; 基因治療; Chronic critical leg ischemia; Vascular endothelial growth factor; Plasmid; Gene therapy; |
語 文 | 中文(Chinese) |
中文摘要 | 從民國89年12月起共有23位病人因慢性危急性下肢缺血病人,接受人類血管內皮生長因子165質體肌肉注射的基因治療。其中3位病人因二個患肢都有問題,隨後也接受注射,因此共有26個患肢接受基因治療。治療劑量由400 (g(N=2)、800 (g(N=5)、1,200 (g(N=4)、1,600 (g(N=7)至2,000 μg (N=8),4週後相同劑量再注射至患部下肢肌肉內,踝/撓動脈壓力指數由0.58±0.04增加到0.72±0.04,血清VEGF濃度由24.6±6.1 pg/ml增加到61.7±10.9 pg/ml,又核磁共振血管攝影也有20患肢改善血流。症狀改善方面,26患肢的疼痛有21患肢獲得改善,而潰瘍的改善則有72%。其中有3患肢因傷口感染,接受截肢處理,又併發症方面,只有6例發生輕微的下肢水腫。本研究顯示以人類血管內皮生長因子165質體,對華人慢性危急性下肢缺血病人施予肌肉注射是安全、可行及有效的。 |
英文摘要 | We enrolled 23 patients with chronic critical leg ischemia from December 2000 to month? year? to investigate the safety and efficacy of intramuscular vascular endothelial growth factor gene therapy. Both limbs were involved and were treated in 3 patients. In total, there were 26 treated limbs. A therapeutic dose of either 400 μg (n=2), 800 μg (n=5), 1200 μg (n=4), 1600 μg (n=7), or 2000 μg (n=8) was injected directly into the muscles of the ischemic limb. The same dose was injected 4 weeks later. The ankle brachial index significantly improved from 0.58±0.04 to 0.72±0.04. Plasma levels of VEGF increased significantly form 24.6±6.1 to 61.7±10.8 pg/ml. Magnetic resonance angiography showed qualitative evidence of improved distal flow in 20 limbs. Resting pain was relived or markedly improved in 21 limbs. Ischemic ulcers healed or markedly improved in 72% of the treated limbs. Amputation was performed in 3 limbs because of wound infection. Complications were limited to mild leg edema in 6 limbs. Our study demonstrated that intramuscular vascular endothelial growth factor gene therapy for ethnic Chinese (i.e., Taiwanese?) patients with chronic critical leg ischemia is safe, feasible, and effective. |
本系統中英文摘要資訊取自各篇刊載內容。